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Abstract
Background: WHO developed a global strategy to eliminate hepatitis B by 2030 and set target to treat 80% of
people with chronic hepatitis B virus (HBV) infection eligible for antiviral treatment. As a first step to achieve this
goal, it is essential to conduct a situation analysis that is fundamental to designing national hepatitis plans. We
therefore estimated the prevalence of chronic HBV infection, and described the existing infrastructure for HBV
diagnosis in Madagascar.
Methods: We conducted a stratified multi-stage serosurvey of hepatitis B surface antigen (HBsAg) in adults aged
≥18 years using 28 sentinel surveillance sites located throughout the country. We obtained the list of facilities
performing HBV testing from the Ministry of Health, and contacted the person responsible at each facility.
Results: A total of 1778 adults were recruited from the 28 study areas. The overall weighted seroprevalence of
HBsAg was 6.9% (95% CI: 5.6–8.6). Populations with a low socio-economic status and those living in rural areas
had a significantly higher seroprevalence of HBsAg. The ratio of facilities equipped to perform HBsAg tests per
100,000 inhabitants was 1.02 in the capital city of Antananarivo and 0.21 outside the capital. There were no
facilities with the capacity to perform HBV DNA testing or transient elastography to measure liver fibrosis.
There are only five hepatologists in Madagascar.
Conclusion: Madagascar has a high-intermediate level of endemicity for HBV infection with a severely limited
capacity for its diagnosis and treatment. Higher HBsAg prevalence in rural or underprivileged populations
underlines the importance of a public health approach to decentralize the management of chronic HBV carriers
in Madagascar by using simple and low-cost diagnostic tools.
Background
Hepatitis B virus (HBV) is a DNA virus belonging to the
Hepadnaviridae family. It is estimated that at least two
billion people have been infected with HBV, and 240
million individuals suffer from chronic HBV infections
[1]. Chronic HBV infection is a major risk factor for liver
disease, including liver cancer [2], one of the most
frequent malignancies in Africa [3]. Hepatitis B has been
largely ignored as an important global health priority
until recently [4], despite the heavy disease burden. In
2015, the United Nations adopted the resolution in the
2030 Agenda for Sustainable Development, in which
viral hepatitis became one of the targeted infectious dis-
eases within the United Nations’ development goals.
Subsequently, the World Health Organization (WHO)
has developed a strategy to eliminate HBV as a public
health threat by 2030, aiming to reduce the incidence of
new chronic infections by 90% and HBV-related mortal-
ity by 65%. Increasing the coverage of HBV testing and
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antiviral treatment became one of the important targets
[4], and the feasibility of a community-based HBV
screening and linkage to care with antiviral therapy in
resource-limited settings was recently demonstrated by
the PROLIFICA project in West Africa [5].
Madagascar is a large island located in the Indian
Ocean close to the southeast of the African continent,
with 23.5 million inhabitants. Although the hepatitis B
vaccine was integrated into the national immunization
program in 2002, vaccination is only provided as part
of the pentavalent vaccine given after the age of
6 weeks, without scheduling a dose at birth. Moreover,
the coverage of three doses of hepatitis B vaccine in
infants was estimated at 69% in 2015, which is
inadequate [6]. There is no national hepatitis plan or
program to screen, diagnose, or treat chronic HBV
carriers. A recent systematic review of the global sero-
prevalence of HBsAg using data from seven previous
serosurveys reported a pooled estimate of 4.6% (95%
CI: 4.4–4.8%) in Madagascar [1]. However, these sur-
veys were limited because they only sampled partici-
pants from one or two locations in the country [7–14].
As a first step to achieve the WHO’s global elimination
strategy, it is essential to better estimate HBV prevalence
in the population before designing national strategies.
We therefore conducted a country-wide serosurvey to
estimate the seroprevalence of HBsAg in adults in
Madagascar and to identify factors associated with it.
We also described the current infrastructure for HBV
testing and treatment in the country.
Methods
Study population
We conducted a stratified multi-stage sample serosurvey
between November 2011 and May 2013. We used senti-
nel surveillance sites for febrile illness as a primary sam-
pling unit to obtain representative samples of the
general population in Madagascar, because these are
evenly scattered throughout the country [15]. We ex-
cluded three of 31 health centres that participate in this
surveillance system (Maroantsetra, Sainte Marie, and
Maintirano) because access to these sites required air
travel. The remaining 28 sites were used to select study
villages (Fig. 1). We stratified the coverage area of each
of the 28 health centres into ‘central’ and ‘peripheral’ de-
pending on the distance from the health centre. Then,
by using a random number generator (Excel, Microsoft)
we randomly selected one village from a central area
and another from a peripheral area. Overall, we assessed
28 central villages and 28 peripheral villages. We ran-
domly selected households in each village, and the team
of fieldworkers visited these selected households until
they could recruit at least 31 adults aged ≥18 years.
Following written informed consent, we administered
a standardised epidemiological questionnaire and ob-
tained a venous blood sample from study participants.
Collected serum samples were transported to the
Virology Unit of the Pasteur Institute of Madagascar,
and stored at −80 °C.
Serological assay
We detected HBsAg using an in-house ELISA that was
validated at our Virology unit. The in-house assay had
good diagnostic accuracy for the detection of HBsAg
(sensitivity, 95.6% (95% CI, [78.05, 100]; specificity,
100% (95% CI, [80.36, 100], using a commercial chemi-
luminescent microparticle immunoassay (Architect®,
Abbott, USA) as a reference. Briefly, for the in-house
capture-ELISA, a goat polyclonal anti-HBs antibody
(Reference ABIN731303, Germany) was first used.
After binding of the sera, a second goat polyclonal
(biotin) antibody (Reference ABIN731305, Germany)
was used. At the end of the reaction, Streptavidin-HRP
conjugate (Reference RPN 1231 - AEC Amersham)
was added before the revelation step using ABTS®
(Sigma-Aldrich).
Sample size calculation
Assuming that the expected seroprevalence of HBsAg is
10% and the desired width of the 95% confidence inter-
val is ±2% with a design effect of 2.0 [16], the minimum
sample size required was 1729. We recruited at least 31
adults per village since there were 56 villages studied.
Data analysis
Statistical analyses were performed using STATA IC.
11.0 (Stata Corporation, USA). The seroprevalence of
HBsAg was estimated by dividing the number of
HBsAg-positive people by the number of survey partic-
ipants. The estimates were weighted for sampling
probability and adjusted for stratification by central or
peripheral area and clustering in the survey design,
using the “svy” command in STATA. Similarly, a
weighted logistic regression, that accounted for stratifi-
cation and clustering by village, was used to identify
factors associated with HBsAg seropositivity. The fac-
tors of interest included basic demographic variables
(age and sex) and potential barriers to linkage from
HBsAg screening to care (education levels, socio-
economic status (SES), and area of residency) [17–19].
After univariable analysis, the associations between
these covariates and HBsAg seropositivity were ad-
justed for age and sex in multivariable logistic regres-
sion models.
We used principal component analysis (PCA) and
hierarchical cluster analysis (HCA) to define the SES
of each individual. We included the following variables
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known to represent the SES in the PCA: type of wall,
floor, and roof material; type of energy for light and
cooking; sanitation facility; and main assets [20–22].
Hierarchical cluster analysis was performed using raw
individual weights obtained from preliminary PCA
using Ward method. Consolidation was performed
using k-means methods. We classified the villages into
three groups: urban, semi-urban, and rural (Fig. 1).
The urban area was defined to be within an adminis-
trative centre of a district and located on the main
road that connects the main Provinces to the capital
Antananarivo. The semi-urban area is also within an
administrative centre of a district, but not on the main
national road. We categorised a village as rural when
none of the above criteria were met. There is at least
one regional hospital in the urban areas, whereas there
is at least one district hospital in the semi-urban areas.
There are no hospitals in the rural areas; only a pri-
mary health care centre.
Infrastructure for HBV testing/treatment in Madagascar
We determined the number of laboratories or health
facilities that routinely carry out each of the following
tests essential for HBV screening and clinical staging:
HBsAg serology, determination of alanine (ALT) and as-
partate transaminase (AST) levels, detection or quantifi-
cation of HBV DNA, transient elastography (Fibroscan®),
and liver biopsy. We also determined the number of
hepatologists and pharmacies that routinely dispense
antiviral drugs (lamivudine or tenofovir). In April 2016,
we first requested the Ministry of Health to generate a
list of facilities including information on each of these
items. Subsequently we verified the list by contacting a
person responsible at each facility using a standardised
questionnaire. We also gathered data on the cost of each
service. We presented the ratio of the number of facil-
ities with the capacity to test individuals for chronic
HBV infection per 100,000 inhabitants, a method
proposed by the WHO [23].
Fig. 1 Map of study sites in Madagascar describing the different areas defined as Zone 1 for urban (in grey), Zone 2 for sub-urban (in blue) and
Zone 3 for rural (in white)
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Results
Seroprevalence of HBsAg
A total of 1778 participants were recruited from the 28
study areas. Approximately half (50.6%) were men. The
mean age was 37.7 years (SD ± 14.4) and ranged from
18 to 99 years. The overall weighted seroprevalence of
HBsAg was 6.9%, 95% CI [5.6–8.6] (141/1778). The
prevalence varied markedly between villages, ranging
from 0.0% to 26.7%.
Factors associated with HBsAg seropositivity
Table 1 presents the factors associated with HBsAg
seropositivity. There was no clear association between
either age group or sex and the seroprevalence of
HBsAg. The seroprevalence of HBsAg in women of
childbearing age (18–45 years old) was 6.2%, 95% CI
[3.4–8.9] (46/630) (Fig. 2).
Variable characterizing low socio economical level
were mainly wooden combustion use, roof made in
plants, light of the petroleum lamp, dirt floor in the bed-
room and not equipped with toilet (v-test were respect-
ively 31.0, 30.5, 26.05, 24.02 and 22.16); variables
characterizing intermediated socio-economical level
were wood charcoal combustion, sheet roof, electricity
light, TV and cement floor (v-test = 26.2, 25.9, 23.5, 22.9
and 22.0, respectively); variables characterizing the high-
est socio-economical level were computer owning, flash
toilet owning, internet access, car and refrigerator own-
ing (v-test were respectively 31.9, 26.5, 26.0, 22.4 and,
21.8). Repartition of characteristic variables in each SES
level were described in Additional file 1: Table S1. Of
the three potential barriers to linkage to care, low SES
and living in a rural area were significantly associated
with HBsAg seropositivity after adjusting for age and
sex. The middle and high SES groups had a seropreve-
lance of HBsAg that was 0.70 [0.42–1.17] and 0.39
[0.14–1.11] times, respectively, that of the low category
SES group (adjusted p for Wald test for trend = 0.03).
Using the participants living in urban areas as the
reference, the odds ratios were 1.23 [0.71–2.11] for
semi-urban and 1.69 [1.09–2.60] for rural areas (adjusted
p for Wald test for trend = 0.04).
Infrastructure for HBV testing/treatment
Table 2 summarises the current infrastructure for HBV
screening, clinical staging, and treatment in Madagascar.
There were 77 laboratories routinely equipped to per-
form HBsAg serology and liver enzyme tests (AST and
Table 1 Factors associated with HBsAg seropositivity in Madagascar, 2011–2013
N HBsAg- positive, n (weighted %) Crude odds ratios Odds ratios adjusted for age and sex
OR (95% CI) p-value OR (95% CI) p-value
Age (years) 0.5* 0.4*
18–24 380 38 (7.1) 1.00 1.00
25–34 475 41 (7.4) 1.05 (0.50–2.22) 1.08 (0.50–2.34)
35–44 379 26 (7.5) 1.06 (0.58–1.97) 1.09 (0.59–2.01)
≥ 45 542 36 (6.0) 0.84 (0.42–1.65) 0.82 (0.42–1.61)
Gender 0.3 0.3
Female 879 58 (5.8) 1.00 1.00
Male 899 83 (8.1) 1.42 (0.75–2.68) 1.43 (0.76–2.67)
Education 0.7* 0.4*
Illiterate 233 18 (5.5) 1.00 1.00
Primary 668 62 (8.6) 1.62 (0.81–3.21) 1.62 (0.80–3.25)
Secondary 794 49 (5.2) 0.96 (0.47–1.96) 0.91 (0.44–1.88)
University 81 12 (13.5) 2.70 (1.05–6.97) 2.48 (0.93–6.61)
SES 0.03* 0.03*
Low 935 81 (9.4) 1.00 1.00
Middle 753 57 (6.6) 0.69 (0.41–1.15) 0.70 (0.42–1.17)
High 90 3 (3.8) 0.38 (0.13–1.10) 0.39 (0.14–1.11)
Area 0.04* 0.04*
Urban 482 26 (6.0) 1.00 1.00
Semi-urban 516 39 (7.2) 1.22 (0.70–2.12) 1.23 (0.71–2.11)
Rural 780 76 (9.8) 1.71 (1.11–2.64) 1.69 (1.09–2.60)
*The p-value was derived from a test for trends
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ALT). Although many have the capacity to perform
ELISA tests, only three laboratories in the capital rou-
tinely performed ELISA assays for HBsAg detection,
whereas the rest used immunochromatographic point-
of-care assays. These 77 facilities cover only 31 of the
114 administrative districts. Thirty-six (46.8%) of the
laboratories are located in the capital, resulting in a
ratio of 1.03 facilities per 100,000 inhabitants in the
capital region and 0.21 per 100,000 inhabitants out-
side. Furthermore, many of these laboratories are not
fully functional throughout the year because of
limited resources, frequent reagent shortages, and
laboratory equipment failure.
There are only five hepatologists in the country (0.08
and 0.01 per 100,000 inhabitants in Antananarivo and
outside of the capital region, respectively). Three are in
Fig. 2 The age- and sex-specific prevalence of HBsAg seropositivity in Madagascar, 2011–2013
Table 2 Infrastructure for HBV testing/treatment in Madagascar in 2016
Total number No. of facilities in the capital region (Antananarivo) No. of facilities in other regions Price
Public Private Public Private
1. Screening for HBV
HBsAg assay ELISA 3 2 1 0 0 $ 10
Point-of-care test 74 11 22 29 12 $ 2–5
2. Clinical staging
AST & ALT 77 13 23 29 12 $ 2–5
HBV DNA PCR assay 0 0 0 0 0 N/A
Fibroscan® 0 0 0 0 0 N/A
Hepatologist 5 3 0 2 0 N/A
3. Treatment
HBV treatment Lamivudine 1 0 1 0 0 $ 0.7/dose
Tenofovir 0 0 0 0 0 N/A
Abbreviations: ELISA enzyme-linked immunosorbent assay, N/A not applicable
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the capital: two at the largest public medical centre and
one at a peripheral public hospital. Two others are in
two hospitals outside the capital region in Fianarantsoa
and in Mahajanga. None of the hepatologists routinely
perform liver biopsies, and only a few surgeons occa-
sionally perform the procedure. There is no Fibroscan®
device and none of laboratories performs PCR assays for
HBV DNA. When HBV DNA measurement is re-
quested, sera are shipped to a commercial laboratory in
France from the Pasteur Institute of Madagascar. Lami-
vudine is available in only one pharmacy in the capital,
and no pharmacy dispenses tenofovir, even though the
national authority has approved it.
Discussion
We conducted a stratified multi-stage sample serosurvey
to estimate the seroprevalence of HBsAg in Madagascar.
We found that: (i) Madagascar has a high-intermediate
level of endemicity of HBV infection, according to the
WHO classification [1], with a weighted prevalence of
6.9%; and (ii) people with a low SES and those living in
rural areas are more likely to be HBsAg seropositive. We
also revealed a severely limited capacity for the diagnosis
and treatment of chronic HBV in Madagascar.
This is the first study that attempted to estimate the
seroprevalence of HBsAg in Madagascar using a repre-
sentative sample of the country. The prevalence was
weighted to reflect the probability of being included in
the survey [16]. There have been 12 serosurveys for
HBsAg in Madagascar to date (Table 3). However, these
only focused on high-risk groups or a few communities
within the country. By pooling data from these studies, a
country-specific prevalence was recently estimated by
Schweitzer et al. (4.6%, 95% CI [4.4–4.8]), which was
much lower than our estimate (6.9%, 95% CI [5.6–8.6]).
Their pooled estimate was low because of a large influ-
ence from one large study of blood donors in the capital,
Antananarivo, (n = 47,597) which reported a prevalence
of 3.8% [13]. The prevalence in the capital is lower than
in other regions [5], and the risk of HBV infection in
blood donors is likely to differ from that of the general
population, possibly leading to an erroneous estimate.
To reduce HBV-related mortality in Madagascar, hepa-
titis B vaccination alone is insufficient because 6.9% of
adults who established chronic infection before the
introduction of hepatitis B vaccines will continue to
carry elevated risk of dying from HBV-related liver dis-
eases. Alternatively, population-wide screening and
treatment of HBV may reduce these deaths, as suggested
by a recent modelling study [24]. We assessed factors as-
sociated with HBsAg seropositivity to identify sub-
groups of the population with an increased risk of
chronic HBV infection. Such information may help in
the planning of a future “HBV screen and treat” program
in Madagascar. We found that the prevalence did not
vary significantly according to age or sex. However,
we identified that people with a low SES and those
living in rural communities have high HBV prevalence
(9.4% and 9.8%, respectively). This is problematic as
both low SES and rural residence are known barriers
to access to healthcare in sub-Saharan Africa [18, 19].
The WHO recommends a public health approach to
scaling up HBV testing and treatment, by ensuring
the “widest possible access to high-quality services at
the population level” [25]. Our results support the
importance of this approach, and suggest that special
care must be taken to not overlook underprivileged
people or those in rural areas, not only to be equit-
able, but also because of the higher HBV prevalence
in these populations.
Although the current infrastructure for “HBV screen
and treat” in Madagascar is very limited, we still believe
that screening, clinical staging, and treatment of people
with chronic HBV infection will become feasible through
the use of alternative diagnostic tools, as recommended
in the WHO treatment guidelines [25]. First, HBsAg de-
tection by ELISA is only performed in three laboratories
in the capital and none in other regions. However,
immunochromatographic point-of-care tests are avail-
able in many laboratories in the capital region and to a
lesser extent in rural areas at an affordable price (2–5
USD/test). The high diagnostic accuracy of HBsAg
point-of-care tests has been confirmed under field con-
ditions in sub-Saharan Africa [26]. Second, although
there is no Fibroscan® and liver biopsy is rarely per-
formed in Madagascar, many laboratories still have the
capacity to test AST and ALT. The WHO recommends
the use of simple non-invasive markers for fibrosis sta-
ging such as APRI or Fib-4, and these only require basic
laboratory markers including transaminase (AST, ALT)
and platelet count. Third, the lack of capacity to evaluate
HBV DNA levels seems to be a problem as its measure-
ment is essential to define treatment eligibility according
to European or American guidelines [27, 28]. However,
the recent WHO guidelines acknowledged the lack of
access to HBV DNA testing in low- and middle-income
countries, and defined separate treatment criteria for
places where HBV DNA testing is not available. These
alternative criteria do not depend on HBV viral load;
they only require ALT levels and an APRI score [25]. Al-
though tenofovir is currently unavailable in Madagascar,
the cost of antivirals does not need to be an obstacle as
its generic version (50–350 USD/year) can be used. The
most serious obstacle may be the lack of a sufficient
healthcare workforce; there are only 0.02 hepatologists/
100,000 inhabitants. Task shifting of HBV clinical man-
agement from hepatologists to mid-level health workers
(e.g., registered nurses) needs to be carefully considered.
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Our study has limitations. First, although we
attempted to provide an estimate that represents the
entire country, we excluded three of 31 sentinel sites
because of difficulties of access. However, the effect
should be minimal as the number of inhabitants cov-
ered by these sites is relatively small. Second, we only
studied people aged 18 years or above, and did not
assess the prevalence in children. This was the re-
quirement from the funder of this study and sampling
of children was therefore, not authorized by the local
IRB. It is to be noted that we are currently conduct-
ing a study focusing on prevention of HBV in
children called NéoVac (Neonatal Vaccination against
Hepatitis B in Africa), which attempts to understand
potential barriers to implement timely birth dose vac-
cination in Madagascar, Senegal and Burkina Faso.
Third, we did not provide care for those who were
identified to be positive for HBsAg during the sero-
survey. When the study was planned in 2011, this
was not required by the national ethics committee.
Conclusion
The WHO has set a target to treat 80% of eligible people
with chronic HBV infection to eliminate hepatitis B as a
Table 3 Prevalence of HBsAg seropositivity in previous studies (n = 12) and the current study in Madagascar
Author Year
published
HBsAg
assay
Province Study
population
Male (%) Age No. tested No. positive Prevalence
of HBsAg
Oddou [11] 1972 Immunodifusion Antananarivo Blood donors N/R N/R 578 17 2.9%
Capdevieille [30] 1979 PHA Antananarivo Blood donors N/R N/R 4000 217 5.4%
Patients with
liver disease
N/R N/R 100 43 43.0%
Ravaoarinoro [14] 1985 ELISA Antananarivo Blood donors 87.2% 19–63 172 4 2.3%
Patients 55.4% 1–65 186 8 4.3%
Mathiot [31] 1987 Electrosyneresis Antananarivo High-risk
populationa
50.0% N/R 178 7 3.9%
Genin [32] 1988 ELISA Toamasina High-risk
populationa
N/R Mean 27
(14–66)
367 65 17.7%
Antsiranana High-risk
populationa
278 26 9.4%
Toliara High-risk
populationa
258 46 17.8%
Mahajanga High-risk
populationa
228 41 18.0%
Rasamindrakotroka
[33]
1993 ELISA Antananarivo Blood donors 83.9% Range: 18–60 1629 77 4.7%
Morvan [10] 1994 ELISA Antananarivo General
population
52.9% Mean 22.0
(1–86)
456 86 18.9%
Toliara General
population
48.2% Mean 21.1
(1–62)
197 60 30.5%
Boisier [7] 1996 ELISA Antananarivo General
population
45.4% Range: 1–94 243 13 5.3%
Toamasina General
population
678 176 26.0%
Migliani [9] 2000 ELISA Mahajanga General
population
41.9% Median 22.5
(2–93)
654 93 14.2%
Dupinay [8] 2010 ELISA Antsiranana General
population
53.5% Median 29
(15–55)
563 48 8.5%
Randriamanantany
[13]
2011 IC Antananarivo Blood donors 80.5% Mean
33.3 ± 10.4
47,597 1810 3.8%
Randriamahazo
[12]
2015 IC Antananarivo Pregnant
women
0% Mean 26.5
(14–44)
1050 20 1.9%
Andriamandimby 2016 ELISA All provinces General
population
50.3% Mean 37.7
(± 14.4)
1778 141 6.9%b
aHigh-risk population includes prostitutes, prisoners and men who have sex with men
bWeighted
Abbreviations: PHA passive hemagglutination, ELISA enzyme-linked immunosorbent assay, IC immunochromatography, N/R not reported
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public health threat by 2030; globally, only 8% of this
population was estimated to be under treatment in 2015
[29]. It is crucial to adopt a public health approach that
ensures the widest possible access to HBV screening and
care at the population level to achieve this goal in
resource-limited countries [4]. Our study demonstrated
a higher seroprevalence of HBsAg in rural areas where the
access to HBV testing is limited, and in people with a low
SES who may be unable to pay for HBV testing and treat-
ment. This clearly requires the need to decentralize the
management of chronic HBV carriers in Madagascar by
using simple and low-cost diagnostic tools. A similar
exercise deserves to be carried out in other low- and
middle-income countries as this may help in designing an
evidence-based national hepatitis plan.
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